Arcturus Therapeutics (ARCT) Misses Q1 EPS by 411c

Arcturus Therapeutics (NASDAQ: ARCT) reported Q1 EPS of ($0.52), $4.11 worse than the analyst estimate of $3.59. Revenue for the quarter came in at $29.38 million versus the consensus estimate of $205.21 million.

For earnings history and earnings-related data on Arcturus Therapeutics (ARCT) click here.

You May Also Be Interested In

• Hawaiian Electric trades at 8.8x P/E, but wildfire risk clouds value case
• Can-Am to provide $150,000 and vehicles to Farm Rescue over three years
• Gap taps Coach architect Reed Krakoff for $29.95-$498 handbag line